Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | HRAS |
Variant | G12S |
Impact List | missense |
Protein Effect | loss of function |
Gene Variant Descriptions | HRAS G12S does not lie within any known functional domains of the Hras protein (UniProt.org). G12S results in decreased Hras GTPase activity, loss of response to GTPase-activating proteins, leading to activation of downstream signaling pathways and transformation of cultured cells (PMID: 24224811, PMID: 21850009, PMID: 6330729). |
Associated Drug Resistance | |
Category Variants Paths |
HRAS mutant HRAS act mut HRAS G12S HRAS mutant HRAS G12X HRAS G12S |
Transcript | NM_005343.4 |
gDNA | chr11:g.534289C>T |
cDNA | c.34G>A |
Protein | p.G12S |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_176795.5 | chr11:g.534289C>T | c.34G>A | p.G12S | RefSeq | GRCh38/hg38 |
NM_005343 | chr11:g.534289C>T | c.34G>A | p.G12S | RefSeq | GRCh38/hg38 |
NM_001130442.2 | chr11:g.534289C>T | c.34G>A | p.G12S | RefSeq | GRCh38/hg38 |
NM_176795.4 | chr11:g.534289C>T | c.34G>A | p.G12S | RefSeq | GRCh38/hg38 |
NM_176795 | chr11:g.534289C>T | c.34G>A | p.G12S | RefSeq | GRCh38/hg38 |
NM_001130442.3 | chr11:g.534289C>T | c.34G>A | p.G12S | RefSeq | GRCh38/hg38 |
NM_001130442 | chr11:g.534289C>T | c.34G>A | p.G12S | RefSeq | GRCh38/hg38 |
NM_005343.4 | chr11:g.534289C>T | c.34G>A | p.G12S | RefSeq | GRCh38/hg38 |
NM_005343.3 | chr11:g.534289C>T | c.34G>A | p.G12S | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05638698 | Phase II | Balstilimab + QS21 + TG01 QS21 + TG01 | Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer (TESLA) | Active, not recruiting | USA | 0 |